Humanigen, Inc. (HGEN)

8.95 +0.10 (+1.13%) At close: 4:00PM EST

Humanigen, Inc.

533 Airport Boulevard
Suite 400
Burlingame, CA 94005
United States
650 243 3100
http://www.humanigen.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Cameron Durrant M.B.A., M.D., MBA	Chairman & CEO	784.5k	N/A	1960
Mr. Timothy Morris CPA, CPA	CFO & COO	66k	N/A	1962
Mr. David L. Tousley CPA, M.B.A., CPA	Chief Accounting & Admin. Officer, Corp. Sec. and Treasurer	N/A	N/A	1956
Dr. Dale Chappell M.B.A., M.D., MBA	Chief Scientific Officer	N/A	N/A	1970
Dr. Tarek Sahmoud	Chief Medical Officer	N/A	N/A	N/A
Dr. Omar Ahmed Pharm.D.	Sr. VP of Clinical, Medical & Scientific Affairs	N/A	N/A	N/A
Mr. Robert Atwill M.B.A.	Head of Asia-Pacific	N/A	N/A	N/A
Mr. Edward P. Jordan M.B.A.	Chief Commercial Officer	N/A	N/A	1968

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

Corporate Governance

Humanigen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.